A Phase 2b/3, double-blind, randomized, placebo-controlled 48-week safety and efficacy trial of ANAVEX2-73 for the treatment of early Alzheimer’s disease

Occurring Dates: 
05/07/2018 to 31/08/2020
Participant Duration: 
12 months
State of study: 
New South Wales
Queensland
South Australia
Western Australia
Victoria
Overview: 

Anavex Life Sciences is seeking volunteers to participate in a new clinical trial for people with mild Alzheimer's disease. ANAVEX2-73 is a small molecule that has shown in research studies to improve mental activities that are involved in learning, remembering and using general daily knowledge. These results are associated with ANAVEX2-73 possibly having protective properties on the brain neurons (brain nerve cells) that are usually damaged in Alzheimer’s disease. It is thought that ANAVEX2-73 acts by attaching to and activating specific proteins called “survival receptors” and this may enable ANAVEX2-73 to modify the disease.

Participation in this study will involve taking a daily oral tablet (ANAVEX2-73 or placebo) and visiting a research centre for 8 study appointments over a 48 week period. To be eligible to participate, participants must be:

  • Between 60 and 85 years of age
  • Have a diagnosis of mild Alzheimer's disease
  • Have a study partner able attend study appointments
  • Can read and converse in English
Further Information: 

If you think this sounds interesting and would like to know more, please register your details at www.anavexaustralia.com or phone (02) 8437 7355.

The Frankston (VIC) trial site can be contacted on (03) 9770 1579 and the NeuroCentrix (VIC) trial site can be contacted on (03) 9546 0009 or at maca@ntvic.com.au.

A full list of study locations is available at: https://clinicaltrials.gov/ct2/show/NCT03790709.

This research has been approved by St Vincents Hospital (Melbourne) Ethics Committee (Project Number: 123/18).

Full Name: 
A/Prof Stephen Macfarlane
Institute: 
HammondCare
Email: 
alzheimerstrials@hammond.com.au
Phone Number: 
(02) 8437 7355